Our coverage:

NanoViricides (NNVC) earnings: expect 0% EPS growth

Carla Olson | 5:17 pm ET, 09 Jun 2019

NanoViricides (NNVC) is announcing earnings on June 10. We combed through analyst estimates to understand what the company revenue and earnings are predicted to look like.

What should you expect from the upcoming earnings?

Earnings per share are expected to come in at $-0.03. If this materializes, EPS will grow 0% year-over-year.

How did the stock do last month?

Over the last month, NanoViricides (NNVC) returned +9.39%.

What do analysts say about the stock?

NanoViricides (NNVC) average analyst price target is 138.1% above its current price ($0.25).

For the latest price and information on NanoViricides, please visit Finstead and ask for "NNVC", "NNVC analysis" or "NNVC news".

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finstead Bites, please send us an email at hi@finstead.com.


NanoViricides (NNVC) earnings: expect NaN% revenue decline

Carla Olson | 2:39 am ET, 15 May 2019

NanoViricides (NNVC) is announcing earnings on May 20. We combed through analyst estimates to understand what the company revenue and earnings are predicted to look like.

What should you expect from the upcoming earnings?

Revenue for the next quarter is expected to be $N/A.

Earnings per share are expected to come in at $-0.03. If this materializes, EPS will grow 0% year-over-year.

How did the stock do last month?

Over the last month, NanoViricides (NNVC) returned -15.25%.

What do analysts say about the stock?

NanoViricides (NNVC) average analyst price target is 130.77% above its current price ($0.26).

For the latest price and information on NanoViricides, please visit Finstead and ask for "NNVC", "NNVC analysis" or "NNVC news".

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finstead Bites, please send us an email at hi@finstead.com.


NanoViricides, Inc. (NNVC) Buy or Sell Stock Guide

Updated at: 11:05 am ET, 12 Jun 2019

Are you looking for the analysis of NanoViricides, Inc. (NNVC) stock? Are you wondering what the bulls and the bears say about it?

If so, you came to the right place. In this stock guide, we will share with you 2 reasons to buy NNVC stock. You’ll get a perspective on what the bulls and the bears say about it.

The analysis below may be also helpful to you if you have any of the following questions about NNVC stock:

  • Is NNVC a buy or a sell?
  • Should I sell or hold NNVC stock today?
  • Is NNVC a good buy / investment?
  • What are NNVC analyst opinions, recommendations and ratings?

Let’s start with the bull case. Here are the reasons to buy NNVC stock:

1. NNVC stock price ($0.25) is close to the 52-week low ($0.20). Perhaps now is a good time to buy? See NNVC price chart.

2. NNVC Price/Book ratio is 1.38, and it’s low compared to its industry peers’ P/B ratios. See NNVC forward Price/Book ratio chart.

There are no NNVC stock sell reasons/signals.

Now let's look at the key statistics for NNVC:

Metrics NNVC
Price $0.24
Average Price Target / Upside N/A
Average Analyst Rating N/A
Industry Drug Manufacturers - Major
Sector Healthcare
Number of Employees 30
Market Cap $21.10M
Forward P/E Ratio -1.45
Price/Book Ratio N/A
PEG N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin N/A

What are your thoughts on NNVC?

If you liked this analysis, check out Buy or Sell Stock Guides for other stocks.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finstead Bites, please send us an email at hi@finstead.com.


Try Finstead: the fastest way to get market data and insights on stocks, ETFs, mutual funds, and cryptocurrencies